ArticleBMC neurology2026
Clinical study on the combined predictive value of admission neutrophil-to-lymphocyte ratio and stress hyperglycemia ratio for early neurological deterioration in acute ischemic stroke.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly neurological deterioration (END) affects short-term prognosis in acute ischemic stroke. Inflammation and stress-related glucose dysregulation may contribute to END, but their incremental predictive value remains unclear.
objectiveTo evaluate the associations of admission neutrophil-to-lymphocyte ratio (NLR) and stress hyperglycemia ratio (SHR) with END and assess whether adding these biomarkers to clinical variables improves risk discrimination.
methodsThis single-center retrospective cohort study included 180 patients with acute ischemic stroke admitted between January 2021 and December 2024. NLR was calculated as neutrophil/lymphocyte ratio. SHR was calculated as admission glucose/estimated average glucose and rescaled as SHR_0.1 = SHR/0.1 before regression, so that the OR represented each 0.1-unit increase. END was defined as an NIHSS increase ≥ 2 within 72 h. Multivariate logistic regression and ROC analysis were performed.
resultsEND occurred in 38 patients (21.1%). NLR was independently associated with END per 1-unit increase (OR = 1.193, 95% CI 1.071-1.328, P = 0.001). Rescaled SHR was independently associated with END per 0.1-unit increase (OR = 1.241, 95% CI 1.082-1.424, P = 0.002). The basic clinical model had an AUC of 0.793, whereas adding NLR and SHR increased the AUC to 0.884.
conclusionAdmission NLR and rescaled SHR were independently associated with END. Adding these routine biomarkers to clinical variables may improve early END risk stratification, pending external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.